308 related articles for article (PubMed ID: 30080284)
1. Ten-year observational follow-up of a randomized trial comparing cyclosporine and tacrolimus therapy combined with steroid withdrawal in living-donor renal transplantation.
Kim J; Park J; Hwang S; Yoo H; Kim K; Park JB; Jang HR; Lee JE; Kim SJ; Kim YG; Kim DJ; Oh HY; Huh W
Clin Transplant; 2018 Sep; 32(9):e13372. PubMed ID: 30080284
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up.
Lee YJ; Kim B; Lee JE; Kim YG; Kim DJ; Kim SJ; Joh JW; Oh HY; Huh W
Transpl Int; 2010 Feb; 23(2):147-54. PubMed ID: 19744223
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
[TBL] [Abstract][Full Text] [Related]
5. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
6. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation.
Guethoff S; Meiser BM; Groetzner J; Eifert S; Grinninger C; Ueberfuhr P; Reichart B; Hagl C; Kaczmarek I
Transplantation; 2013 Feb; 95(4):629-34. PubMed ID: 23423270
[TBL] [Abstract][Full Text] [Related]
7. Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: Results of a randomized trial.
Tönshoff B; Ettenger R; Dello Strologo L; Marks SD; Pape L; Tedesco-Silva H; Bjerre A; Christian M; Meier M; Martzloff ED; Rauer B; Ng J; Lopez P
Am J Transplant; 2019 Mar; 19(3):811-822. PubMed ID: 30125462
[TBL] [Abstract][Full Text] [Related]
8. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids.
Bunnapradist S; Daswani A; Takemoto SK
Transplantation; 2003 Jul; 76(1):10-5. PubMed ID: 12865780
[TBL] [Abstract][Full Text] [Related]
9. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
Ulsh PJ; Yang HC; Holman MJ; Ahsan N
J Transpl Coord; 1999 Jun; 9(2):114-8. PubMed ID: 10703393
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.
Ahsan N; Johnson C; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
Transplantation; 2001 Jul; 72(2):245-50. PubMed ID: 11477347
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
Qazi Y; Shaffer D; Kaplan B; Kim DY; Luan FL; Peddi VR; Shihab F; Tomlanovich S; Yilmaz S; McCague K; Patel D; Mulgaonkar S
Am J Transplant; 2017 May; 17(5):1358-1369. PubMed ID: 27775865
[TBL] [Abstract][Full Text] [Related]
12. Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation.
Wissing KM; Abramowicz D; Weekers L; Budde K; Rath T; Witzke O; Broeders N; Kianda M; Kuypers DRJ
Am J Transplant; 2018 Jul; 18(7):1726-1734. PubMed ID: 29337426
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE
Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of tacrolimus versus cyclosporine in steroid withdrawal in living donor renal transplant recipients.
Kim SJ; Lee KW; Lee DS; Lee HH; Lee SK; Kim B; Huh WS; Oh HY; Joh JW
Transplant Proc; 2004 Sep; 36(7):2098-100. PubMed ID: 15518759
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients.
Silva HT; Yang HC; Meier-Kriesche HU; Croy R; Holman J; Fitzsimmons WE; First MR
Transplantation; 2014 Mar; 97(6):636-41. PubMed ID: 24521771
[TBL] [Abstract][Full Text] [Related]
17. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
18. Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy.
Sommerer C; Duerr M; Witzke O; Lehner F; Arns W; Kliem V; Ackermann D; Guba M; Jacobi J; Hauser IA; Stahl R; Reinke P; Rath T; Veit J; Mehrabi A; Porstner M; Budde K;
Am J Transplant; 2018 Dec; 18(12):2965-2976. PubMed ID: 29722128
[TBL] [Abstract][Full Text] [Related]
19. A prospective randomized study comparing cyclosporine versus tacrolimus combined with daclizumab, mycophenolate mofetil, and steroids in heart transplantation.
Sánchez-Lázaro IJ; Almenar L; Martínez-Dolz L; Buendía-Fuentes F; Agüero J; Navarro-Manchón J; Vicente JL; Salvador A
Clin Transplant; 2011; 25(4):606-13. PubMed ID: 20682020
[TBL] [Abstract][Full Text] [Related]
20. Once-daily vs twice-daily tacrolimus for de novo living kidney transplantation patients including ABO/HLA compatible and incompatible: A randomized trial.
Okumi M; Unagami K; Furusawa M; Kakuta Y; IIzuka J; Takagi T; Shirakawa H; Shimizu T; Omoto K; Inui M; Ishida H; Tanabe K
Clin Transplant; 2018 Dec; 32(12):e13423. PubMed ID: 30318624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
